Stem Cell Therapeutics Corp. Announces $2 Million Equity Offering

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT" or "Stem Cell
Therapeutics") announces that it has entered into an agency agreement and has
carried-out an overnight marketed offering to sell up to 18,181,819 Units at a
price of $0.11 per Unit, representing gross proceeds of $2 million. Each Unit is
comprised of one common share and one-half of one common share purchase warrant.
Each full warrant will have an exercise price of $0.16, exercisable for a period
of 3 years following the closing date of the offering. The offering is being
conducted by Euro Pacific Canada Inc., as agent, and Bloom Burton & Co., as
selling firm. The offering jurisdictions include the provinces of British
Columbia, Alberta, Manitoba, Ontario and Nova Scotia by way of a prospectus
supplement to SCT's base shelf prospectus dated March 1, 2011. The agency
agreement in respect of the offering provides for a 24 hour due diligence period
in favour of the agents.


SCT intends to use the net proceeds from the offering to fund the advancement of
its ongoing research and development activities, working capital and other
general corporate purposes, which may include SCT's clinical trial program. The
transaction is expected to close on or about March 31, 2011, subject to the
satisfaction of all necessary regulatory approvals, including the approval of
the TSX Venture Exchange.


This news release shall not constitute an offer to sell nor the solicitation of
an offer to buy nor shall there be any sale of these securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of any such
jurisdiction.


About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public
biotechnology company (TSX VENTURE:SSS) focused on the development and
commercialization of drug-based therapies to treat central nervous system
diseases. SCT is a leader in the development of therapies that utilize drugs to
stimulate a patient's own resident stem cells. The Company's programs aim to
repair brain and nerve function lost due to disease or injury. The Company's
extensive patent portfolio of owned and licensed intellectual property supports
the potential expansion into future clinical programs in numerous neurological
diseases such as stroke, traumatic brain injury, multiple sclerosis,
Huntington's disease, Alzheimer's disease, and ALS.


These securities have not been registered under the United States Securities Act
of 1933, as amended, or the securities laws of any state, and may not be offered
or sold within the United States or to, or for the account or benefit of U.S.
persons unless an applicable exemption from U.S. registration requirements is
available.


Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.